Oct. 15 at 1:29 PM
$ACTU Where Breakthrough Science Meets Real-World Impact 🧬💥
Actuate Therapeutics is developing next-generation therapies for aggressive and treatment-resistant cancers, using precision science to target key disease pathways and improve patient outcomes.🧪
Its lead candidate, elraglusib, has demonstrated significant survival benefits in pancreatic cancer, doubling 1-year survival rates and enhancing treatment response.📈
Through partnerships with Harvard Medical School and Mass General Brigham, Actuate is advancing its mission with world-class validation and regulatory progress.🤝
By addressing one of medicine’s toughest challenges, pancreatic cancer, Actuate is bringing true innovation to patients who need it most.🧩
With the global oncology drugs market projected to be
$503 billion by 2033,
$ACTU is strategically positioned to lead the next era of innovation in cancer treatment. 🎯
Communicated Disclaimer: https://chartingdaily.com/Actu
Sector Peers:
$JNJ $LLY $MRNA $PFE
